
FDA halts overseas inspections over coronavirus concerns
pharmafile | March 11, 2020 | News story | Research and Development, Sales and Marketing | FDA, US, approvals, pharma
The FDA has responded to the ongoing COVID-19 coronavirus outbreak by announcing that it will halt all inspections of overseas facilities until further notice.
“After careful consideration, the FDA is postponing most foreign inspections through April, effective immediately. Inspections outside the US deemed mission-critical will still be considered on a case-by-case basis,” the agency announced via a release on its website.
The FDA said it considered a range of factors when making the decision, including travel recommendations coming out of the Centers for Disease Control and Prevention, guidance from the Office of Personnel Management, and the State Department Level 4 advice ruling out travel for employees of the US Government.
It also offered the assurance that it was considerate of how the decision will impact other FDA operations such as regulatory reviews, but it was confident in its ability to use alternative methods to maintain its oversight in sync with the federal government.
To this end, the FDA said it would employ previously successful strategies such as physical sampling of products at the border as well as reviewing compliance history of manufacturers and supplementary data from foreign governments, potentially denying the import of suspected non-compliant products.
The agency said it aims to recommence these foreign inspections as soon as it becomes feasible to do so.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …






